Drug Profile


Alternative Names: GX-I7; IL-7-hyFc; Long-acting Interleukin-7

Latest Information Update: 23 Aug 2016

Price : $50

At a glance

  • Originator Genexine
  • Class Antineoplastics; Antivirals; Interleukins
  • Mechanism of Action Interleukin 7 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Human papillomavirus infections; Leucopenia
  • Preclinical Solid tumours

Most Recent Events

  • 01 Jul 2016 Phase-I clinical trials in Human papillomavirus infections in South Korea (SC) (Genexine pipeline, August 2016)
  • 01 Jul 2016 Phase-I clinical trials in Leucopenia in South Korea (SC) (Genexine pipeline, August 2016)
  • 01 Jul 2016 Preclinical trials in Solid tumours in South Korea (SC) (Genexine pipeline, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top